| REA (repressor of estrogen receptor activity, also known as Prohibitin-2/PHB2 in this context) is a broadly expressed nuclear coregulator that associates with estrogen receptor α (ERα) and other nuclear receptors to modulate transcriptional responses to estradiol in a gene‑, tissue‑, and stage‑specific manner, acting predominantly as a brake on estrogen signaling in reproductive tissues and hormone‑responsive epithelia. The protein contains an N‑terminal coiled‑coil/PHB domain that supports oligomerization and interaction with other prohibitin-family members and chromatin regulators, and a C‑terminal region harboring nuclear receptor interaction motifs and sites for post‑translational modification that tune its affinity for ERα and its ability to recruit corepressor or coactivator complexes. REA binds ERα on chromatin and influences the composition of ER transcriptional complexes by constraining the recruitment of p160 coactivators and histone acetyltransferases and by favoring the assembly of complexes that include NCoR/SMRT and histone deacetylases, which diminishes estrogen‑induced histone acetylation and limits the amplitude and duration of ER target gene activation. Uterine studies using conditional and allelic series models show that partial reduction of REA enhances estrogen‑stimulated proliferation, increases expression of ERα target genes, and exaggerates uterine growth responses, whereas complete loss of REA impairs appropriate coordination of proliferation and differentiation and disrupts implantation, demonstrating a dosage‑dependent requirement for REA in setting the physiological window of ER responsiveness. REA also modulates cross‑talk between estrogen-responsive epithelial, stromal, and immune cell populations in the uterus: altered REA levels shift the balance of paracrine signaling factors and inflammatory mediators, changing the local microenvironment and influencing processes such as endometrial receptivity and decidualization. In the mammary gland, REA plays stage-specific roles, where appropriate corepressor activity constrains ductal growth during puberty and pregnancy, while partial loss of REA increases ER target gene expression and accelerates side-branching and alveologenesis, linking its coregulatory function to the architecture and differentiation of mammary epithelium. Dysregulated REA expression or function in breast cancer has been associated with altered ERα signaling output, where reduced REA levels correlate with heightened estrogen-driven transcription and increased proliferation, while maintenance of REA-mediated repression contributes to control of ER target genes implicated in tumor growth and endocrine response. |
